CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...

Shares of BridgeBio Pharma (NASDAQ:BBIO), currently valued at $5.88 billion, witnessed an uptick as Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target to $49 from $48 while ...

Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol) ...

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEM ...

Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate of $3.42. Earnings rose 17% year over year on a reported basis, boosted by ...

NanoViricides, Inc. (NYSE American:NNVC) (the 'Company') declared today that it is ready to fight the bird flu with its revolutionary ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.